Cyclacel acquires Plogosertib assets from liquidated subsidiary for £250K

Bio Green Med Solution, Inc.

Cyclacel Pharmaceuticals buys PLK1 inhibitor Plogosertib assets from wholly-owned UK subsidiary in liquidation for £250,000.
Includes patent rights, API, CMC data, preclinical and clinical data, and know-how related to Plogosertib.
Buyer agrees to only sell assets for cash consideration within 24 months; any surplus (50% of net proceeds) paid to subsidiary.
Transaction closed on March 10, 2025; Patent Assignment Agreement also executed.
Debt/liabilities of seller not assumed; buyer responsible for subsequent disposal surplus payments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.